Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study

Abstract

In the US population, the prevalence of CM was nearly 1%. In adjusted models, CM prevalence was highest among females, in mid-life, and in households with the lowest annual income. Severe headache-related disability was more common among persons with CM and most common among females with CM.

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

“…Preventive treatment regimens are often critical to ensuring optimal patient outcomes. The goals of migraine preventive therapies include: (1) reduction in attack frequency, severity, and duration; (2) improved responsiveness to acute treatments; (3) decreasing disability and improving overall function; (4) preventing analgesic overuse and “transformation” to chronic daily headache; and (5) reduction of overall cost of treatment 4, 36…”

“…The AMPP Study showed that the majority of individuals with CM had not received a correct diagnosis (79.8%) nor specific acute (68.4%) or preventive (60.0%) medications. These data suggest that most patients with CM are not crossing the 3‐step series of barriers and thus are not effectively managed 4, 17…”

“…EM is characterized by migraine with headache attacks that occur <15 days per month, whereas CM is generally characterized by ≥15 headache days per month with migrainous features ≥8 days per month 1. Within the US migraine population, the majority (93.3%) are classified as having EM, but those who have CM (7.7%)4 are recognized as the segment suffering most from the disorder. Supported by clinical experience, data have demonstrated that compared with people with EM, those with CM experience substantially greater headache impact on daily activities,5, 6 higher direct medical costs,7, 8, 9 greater healthcare resource utilization,5 reduced health‐related quality of life,5, 10 and higher rates of comorbidities 11, 12…”

Trend of Use of Different Antimigraine Medications and Awareness of Migraine, Survey Based Study in Jalandhar

“…According to the recent theory, vasoactive neuropeptides released by trigeminal nerve terminals travel to the outer covering of the brain (meninges) causes inflammation and dilation of meningeal blood vessels. Serotonin (5-HT) and magnesium level decreases during migraine which causes vasodilatation and tend to cause migraine attack [12]. According to this concept, calcitonin gene related peptide (CGRP) is a neurotransmitter, which leads to the release of proinflammatory cytokines from the meningeal mast cells cause vasodilatation and leads to migraines headache [1].…”

The effectiveness of aspirin for migraine prophylaxis: a systematic review

“…4 In Latin America, a multicenter study conducted in Argentina, Brazil, Colombia, Mexico and Venezuela found that 62% of the participants suffered from headaches, and that the prevalence of migraine among women was 6.1% to 17.4%, while that among men was 2.9% to 7.8%. 5 Furthermore, several studies have identified a subgroup of patients who experience chronic migraine, 6,7 in which headache occurs on at least 15 days per month for more than 3 months, 2,8 with features of migraine headache on at least 8 days per month.…”